Peking University
International Symposium 2018
Sponsor Prospectus
Sep. 15-16, 2018
Beijing
Nowadays, the global drug development entered the new biopharma era. The exploration of human origin mechanism is getting deeper and deeper. New technology, new methods, new diagnoses and new therapies emerge constantly. The regulators launch several regulation reforms to promote the efficient and safe drug into market as soon as possible in accordance with the updated drug development model. Meanwhile, the blooming market also attracts a large amount of investment, which brings business prosperity and severe competition.
To forecast the year 2020 in the year 2018, those who look far and wide and grasp the trends can win the market and competition.
The Peking University will hold the International Symposium “The New BioPharma Era: Innovations and Breakthroughs of 2020” together with prestigious global biopharma companies in the fall of 2018. The Symposium sincerely invite you to join in the big event and share the latest ideas.
Prof. Weigang Fang
Director,
Peking University Clinical Research Institute
More masters will be invited in 2018
Bruce Johnson, MD, Professor,
ASCO President, Harvard
MC Fung, MD,
Symposium Chairman,
Adjunct Professor of Peking University
Clinical Research Institute,
Former VP of JNJ Oncology Innovation
Fan BAI, Professor,
Peking University,
Gene Sequencing
Zhifei DAI, Professor,
Peking University,
Nanotechnology
Demin ZHOU, Professor,
Peking University,
Gene Therapy
Huiqiu ZHU, Professor,
Peking University,
Microbiome
Heng ZHU, PhD, Professor,
The Johns Hopkins University, Proteomics
Liwei WANG, Professor,
Peking University,
Artificial Intelligence
Hongkui DENG, Professor,
Peking University,
Stem Cells
Wengong WANG, Professor,
Peking University,
Anti-aging
Ruilin SONG, Executive President,
PhIRDA,
IPO
Peng JIN, Professor,
Emory University,
Genetic Disease Detection
Wensheng WEI , Professor,
Peking University,
Gene Editing
Zemin ZHANG, Professor,
Peking University,
Gene Sequencing
Dong Wang, PhD, Professor,
\u000bSchool of Medicine, Tsinghua University,
Oncogenomics
Luxia ZHANG,
Chief Physician,
Peking University First Hospital,
Big Data
Guangping Gao, PhD, Professor, University of Massachusetts Medical School,
Gene Therapy
Haoxin XU, Professor,
University of Michigan,
Autophagy and Lysosomes
Guobing XU, Professor,
Beijing Cancer Hospital,
Detection and Diagnosis
Guoli MING, Professor,
University of Pennsylvania,
Stem Cells and Heredity
Hongjun SONG, Professor,
University of Pennsylvania,
Stem Cells and Neuroscience
Kaichun WU, Professor,
Chief Physician,
The Fourth Military Medical University,
CAR-T, Cell Therapy
Zhongjun LIU, Professor,
Chief Physician,
Peking University Third Hospital,
3D Printing
Jiang QIAN, Professor,
The Johns Hopkins University,
Bioinformatics and Artificial Intelligence
William JIA, PhD, Professor,
Department of Surgery,
University of British Columbia, Canada,
Oncolytic Virus
Han-Chong Toh, MD, Professor,
Senior Consultant and Deputy Director, National Cancer Center, Singapore,
Cancer Vaccine
TOPICS (Tentative)
SPONSORSHIP LEVELS
Peking University International Symposium 2017
IO v2.0 – Second Wave Cancer Immunotherapy and Combination Strategies
2017 PKU Intl Symposium attracted more than 300 people onsite, coming from government, bio-pharmaceuticals, scientific research institutions, hospitals, investment circus, legal units and medical media. Over 100 insiders from Boston, San Francisco, Santiago, Princeton, Toronto, Singapore, Beijing, Tianjin, Nanjing, Suzhou, Chengdu, Wuhan, Chongqing, Guangzhou, Shenzhen, Guiyang, Hong Kong, Taipei, etc. participated the Symposium via webcast.
ATTENDEES
30 International Pharma /CRO
82 Local Pharma /CRO
9 Investment Companies
22 Universities/ Scientific Research Institutions
5 Hospitals
China Food and Drug Administration (Now China National Drug Administration)
Contact Information
Sandy ZHANG
Tel:86-10-82805563-506
86-13811049599
E-mail: pucri_zhangxf@bjmu.edu.cn
